EpiGene

EpiGene is a biotechnology startup based in Russia, founded in 2014. The company's slogan, "New generation of epigenetic PCR tests for early cancer detection," encapsulates its focus on developing next-generation epigenetic tests for early cancer detection. As a spin-off of SibEnzyme, EpiGene has garnered attention as a Skolkovo resident and has attracted investment from Nanocenter SYGMA. Notably, the company completed its Seed Round investment on 07 December 2016, with Skolkovo Foundation and SYGMA.Novosibirsk as its investors. EpiGene has made significant strides in developing tests for the early detection of lung, breast, stomach, and colon cancers and is currently seeking partnerships to expand its reach globally. With a strong focus on leveraging epigenetics for cancer detection, EpiGene presents an innovative approach to addressing the challenge of early diagnosis, offering potential for significant impact in the field of oncology.